<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="217081">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258921</url>
  </required_header>
  <id_info>
    <org_study_id>R-9511</org_study_id>
    <nct_id>NCT00258921</nct_id>
  </id_info>
  <brief_title>RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment</brief_title>
  <acronym>RIAT</acronym>
  <official_title>An International Registry in Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To support physicians in their active management of hypertensive patients. By targeting
      specific systolic and diastolic blood pressure (BP) figures physicians will closely monitor
      the BP values and as such will have an individualized control of the treatment in each
      patient.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>31870</enrollment>
  <condition>Hypertension</condition>
  <eligibility>
    <criteria>
      <textblock>
        The following information on clinical trials is provided for information purposes only to
        allow patients and physicians to have an initial discussion about the trial. This
        information is not intended to be complete information about the trial, to contain all
        considerations that may be relevant to potential participation in the trial, or to replace
        the advice of a personal physician or health professional.

        Main criteria are listed hereafter:

        Inclusion Criteria:

          -  Adult hypertensive

          -  Either newly diagnosed and untreated

          -  or previously treated and uncontrolled Patients of both sexes with essential
             hypertension

        Exclusion Criteria:

          -  Known secondary hypertension

          -  Known secondary curable hypertension (i.e. pheochromocytoma, aldosterone producing
             adenoma, Cushing disease). Patients with renal disease are not excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale BLONDIN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>November 2007</verification_date>
  <lastchanged_date>November 21, 2007</lastchanged_date>
  <firstreceived_date>November 24, 2005</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
